{"id":"lifileucel-plus-pembrolizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Immune-related adverse events (from pembrolizumab)"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL3137343","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lifileucel involves isolating tumor-infiltrating lymphocytes from a patient's own tumor, expanding them ex vivo to large numbers, and reinfusing them back into the patient. Pembrolizumab, a PD-1 checkpoint inhibitor, is administered concurrently to block PD-1/PD-L1 interactions and further enhance T-cell activation and persistence. Together, this combination aims to maximize tumor-specific T-cell recognition and killing of cancer cells.","oneSentence":"Lifileucel is an autologous tumor-infiltrating lymphocyte (TIL) therapy that expands patient-derived T cells from their tumor and reinfuses them alongside pembrolizumab, a PD-1 inhibitor, to enhance anti-tumor immune response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:55.904Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT05176470","phase":"PHASE1","title":"Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Richard Wu","startDate":"2022-07-01","conditions":"Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","enrollment":2},{"nctId":"NCT05727904","phase":"PHASE3","title":"Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2023-03-30","conditions":"Metastatic Melanoma, Unresectable Melanoma, Melanoma","enrollment":670},{"nctId":"NCT03645928","phase":"PHASE2","title":"Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2019-05-07","conditions":"Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer","enrollment":245},{"nctId":"NCT06190249","phase":"PHASE1","title":"Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma","status":"WITHDRAWN","sponsor":"James Isaacs, MD","startDate":"2024-12-02","conditions":"Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IIID Melanoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LN-144","Pembrolizumab"],"phase":"phase_3","status":"active","brandName":"Lifileucel plus Pembrolizumab","genericName":"Lifileucel plus Pembrolizumab","companyName":"Iovance Biotherapeutics, Inc.","companyId":"iovance-biotherapeutics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Lifileucel is an autologous tumor-infiltrating lymphocyte (TIL) therapy that expands patient-derived T cells from their tumor and reinfuses them alongside pembrolizumab, a PD-1 inhibitor, to enhance anti-tumor immune response. Used for Metastatic melanoma (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}